Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioLineRx has entered into a worldwide, exclusive license agreement with Genoscience and RFS Pharma to develop and commercialize BL-8030, an orally available treatment for Hepatitis C.
Subscribe to our email newsletter
The agreement includes milestones, upfront license fees and royalties payable to both the companies.
The terms of the agreement are consistent with BioLineRx’s standard in-license agreements.
BL-8030 is a potent and selective second generation NS3 protease inhibitor.
The NS3 protease is essential for the replication of the Hepatitis C virus (HCV) and is an important target for HCV therapies.
BL-8030 has been shown to have antiviral activity against various HCV genotypes.
RFS chemistry senior director Steven Coats said they worked closely with the group at Genoscience to determine the optimum characteristic that led to discovery of BL-8030 and related protease inhibitors.